ImmunityBio Shares Fall 7% Despite New Patient Preference Data Presentation

(RTTNews) - ImmunityBio, Inc. (IBRX) shares declined 6.65 percent to $7.22, down $0.51 on Friday, despite the company presenting new patient survey findings related to bladder cancer treatment preferences at ISPOR 2026.

The stock is currently trading at $7.22, compared with a previous close of $7.74 on the Nasdaq. It opened at $7.64 and traded between $7.17 and $7.69 during the session, with volume reaching 6.78 million shares, below the average daily volume of 22.81 million shares.

ImmunityBio Inc. released data from a mixed-methods study conducted with Fight Bladder Cancer examining treatment priorities among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

The study found that patient preferences varied widely depending on age, prior treatment experience, and quality-of-life considerations. Patients currently receiving BCG treatment generally preferred bladder-preserving approaches, while those who had previously undergone radical cystectomy were more likely to support repeating the procedure.

ImmunityBio shares have traded between $1.95 and $12.43 over the past 52 weeks.